Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine

P. L. Zinzani, M. Magagnoli, M. Bendandi, M. Tani, V. Stefoni, C. Cellini, S. Poggi, M. Piccioli, S. Pileri, S. Tura

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background and Objectives. The management of patients with hairy cell leukemia (HCL) has evolved significantly over the past two decades. In fact, both 2-deoxycoformycin (DCF) and 2-chlorodeoxyadenosine (2-CdA) induce complete response (CR) in the majesty of the patients with HCL. However, fewer data exist on the long-term follow-up of patients who have undergone the characteristically brief exposure to 2-CdA therapy. Thus, it is impotent to evaluate such long-term outcome data in order to increase understanding of the efficacy of this agent in the management of HCL. Design and Methods. We reviewed the long-term follow-up data of 23 HCL patients pretreated with α-interferon and then treated with 2-CdA administered as a single continuous IV infusion for 7 days at the dose of 0.1 mg/kg/day in our institute between January 1991 and February 1992. Results. Of 23 patients, 19 (83%) achieved a CR and 4 (17%) a partial response (PR), with an overall response rate of 100%. After a median follow-up of 102 months (range: 96-108), there have been 9 (39%) relapses. In the PR subset 100% of patients relapsed within the first 45 months of follow-up. In the group of patients who obtained a CR, 26% relapsed; all these relapses occurred between 54 and 86 months. Overall the median time to relapse was 54 months (range: 16-86). All relapsed patients were retreated with 2-CdA at the dose of 0.15 mg/kg/day for 5 days in a 2-hour infusion, and 67% and 22% then obtained CR or PR, respectively. The russian duramen of this second response was 48 months (range: 22-80). All but one of these patients still maintain the second response to 2-CdA. The 9-year overall and the relapse-free survivals are 91% and 70%, respectively. Interpretation and Conclusions. In HCL patients a single dose of 2-CdA induces a long-term CR with a 9-year survival > 90%. Over 50% of patients appear to be clinically cured by this procedure, but the lack of a long-term plateau in the relapse-free survival curve means caution on this point is still warranted. (C) 2000, Ferrata Storti Foundation.

Original languageEnglish
Pages (from-to)922-925
Number of pages4
JournalHaematologica
Volume85
Issue number9
Publication statusPublished - 2000

Fingerprint

Cladribine
Hairy Cell Leukemia
Recurrence
Survival
Pentostatin
Interferons

Keywords

  • 2-CdA
  • 9-year follow-up
  • HCL
  • Re-treated patients

ASJC Scopus subject areas

  • Hematology

Cite this

Zinzani, P. L., Magagnoli, M., Bendandi, M., Tani, M., Stefoni, V., Cellini, C., ... Tura, S. (2000). Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. Haematologica, 85(9), 922-925.

Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. / Zinzani, P. L.; Magagnoli, M.; Bendandi, M.; Tani, M.; Stefoni, V.; Cellini, C.; Poggi, S.; Piccioli, M.; Pileri, S.; Tura, S.

In: Haematologica, Vol. 85, No. 9, 2000, p. 922-925.

Research output: Contribution to journalArticle

Zinzani, PL, Magagnoli, M, Bendandi, M, Tani, M, Stefoni, V, Cellini, C, Poggi, S, Piccioli, M, Pileri, S & Tura, S 2000, 'Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine', Haematologica, vol. 85, no. 9, pp. 922-925.
Zinzani PL, Magagnoli M, Bendandi M, Tani M, Stefoni V, Cellini C et al. Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. Haematologica. 2000;85(9):922-925.
Zinzani, P. L. ; Magagnoli, M. ; Bendandi, M. ; Tani, M. ; Stefoni, V. ; Cellini, C. ; Poggi, S. ; Piccioli, M. ; Pileri, S. ; Tura, S. / Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. In: Haematologica. 2000 ; Vol. 85, No. 9. pp. 922-925.
@article{245eae7014c74748aeaf297a720270f3,
title = "Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine",
abstract = "Background and Objectives. The management of patients with hairy cell leukemia (HCL) has evolved significantly over the past two decades. In fact, both 2-deoxycoformycin (DCF) and 2-chlorodeoxyadenosine (2-CdA) induce complete response (CR) in the majesty of the patients with HCL. However, fewer data exist on the long-term follow-up of patients who have undergone the characteristically brief exposure to 2-CdA therapy. Thus, it is impotent to evaluate such long-term outcome data in order to increase understanding of the efficacy of this agent in the management of HCL. Design and Methods. We reviewed the long-term follow-up data of 23 HCL patients pretreated with α-interferon and then treated with 2-CdA administered as a single continuous IV infusion for 7 days at the dose of 0.1 mg/kg/day in our institute between January 1991 and February 1992. Results. Of 23 patients, 19 (83{\%}) achieved a CR and 4 (17{\%}) a partial response (PR), with an overall response rate of 100{\%}. After a median follow-up of 102 months (range: 96-108), there have been 9 (39{\%}) relapses. In the PR subset 100{\%} of patients relapsed within the first 45 months of follow-up. In the group of patients who obtained a CR, 26{\%} relapsed; all these relapses occurred between 54 and 86 months. Overall the median time to relapse was 54 months (range: 16-86). All relapsed patients were retreated with 2-CdA at the dose of 0.15 mg/kg/day for 5 days in a 2-hour infusion, and 67{\%} and 22{\%} then obtained CR or PR, respectively. The russian duramen of this second response was 48 months (range: 22-80). All but one of these patients still maintain the second response to 2-CdA. The 9-year overall and the relapse-free survivals are 91{\%} and 70{\%}, respectively. Interpretation and Conclusions. In HCL patients a single dose of 2-CdA induces a long-term CR with a 9-year survival > 90{\%}. Over 50{\%} of patients appear to be clinically cured by this procedure, but the lack of a long-term plateau in the relapse-free survival curve means caution on this point is still warranted. (C) 2000, Ferrata Storti Foundation.",
keywords = "2-CdA, 9-year follow-up, HCL, Re-treated patients",
author = "Zinzani, {P. L.} and M. Magagnoli and M. Bendandi and M. Tani and V. Stefoni and C. Cellini and S. Poggi and M. Piccioli and S. Pileri and S. Tura",
year = "2000",
language = "English",
volume = "85",
pages = "922--925",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "9",

}

TY - JOUR

T1 - Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine

AU - Zinzani, P. L.

AU - Magagnoli, M.

AU - Bendandi, M.

AU - Tani, M.

AU - Stefoni, V.

AU - Cellini, C.

AU - Poggi, S.

AU - Piccioli, M.

AU - Pileri, S.

AU - Tura, S.

PY - 2000

Y1 - 2000

N2 - Background and Objectives. The management of patients with hairy cell leukemia (HCL) has evolved significantly over the past two decades. In fact, both 2-deoxycoformycin (DCF) and 2-chlorodeoxyadenosine (2-CdA) induce complete response (CR) in the majesty of the patients with HCL. However, fewer data exist on the long-term follow-up of patients who have undergone the characteristically brief exposure to 2-CdA therapy. Thus, it is impotent to evaluate such long-term outcome data in order to increase understanding of the efficacy of this agent in the management of HCL. Design and Methods. We reviewed the long-term follow-up data of 23 HCL patients pretreated with α-interferon and then treated with 2-CdA administered as a single continuous IV infusion for 7 days at the dose of 0.1 mg/kg/day in our institute between January 1991 and February 1992. Results. Of 23 patients, 19 (83%) achieved a CR and 4 (17%) a partial response (PR), with an overall response rate of 100%. After a median follow-up of 102 months (range: 96-108), there have been 9 (39%) relapses. In the PR subset 100% of patients relapsed within the first 45 months of follow-up. In the group of patients who obtained a CR, 26% relapsed; all these relapses occurred between 54 and 86 months. Overall the median time to relapse was 54 months (range: 16-86). All relapsed patients were retreated with 2-CdA at the dose of 0.15 mg/kg/day for 5 days in a 2-hour infusion, and 67% and 22% then obtained CR or PR, respectively. The russian duramen of this second response was 48 months (range: 22-80). All but one of these patients still maintain the second response to 2-CdA. The 9-year overall and the relapse-free survivals are 91% and 70%, respectively. Interpretation and Conclusions. In HCL patients a single dose of 2-CdA induces a long-term CR with a 9-year survival > 90%. Over 50% of patients appear to be clinically cured by this procedure, but the lack of a long-term plateau in the relapse-free survival curve means caution on this point is still warranted. (C) 2000, Ferrata Storti Foundation.

AB - Background and Objectives. The management of patients with hairy cell leukemia (HCL) has evolved significantly over the past two decades. In fact, both 2-deoxycoformycin (DCF) and 2-chlorodeoxyadenosine (2-CdA) induce complete response (CR) in the majesty of the patients with HCL. However, fewer data exist on the long-term follow-up of patients who have undergone the characteristically brief exposure to 2-CdA therapy. Thus, it is impotent to evaluate such long-term outcome data in order to increase understanding of the efficacy of this agent in the management of HCL. Design and Methods. We reviewed the long-term follow-up data of 23 HCL patients pretreated with α-interferon and then treated with 2-CdA administered as a single continuous IV infusion for 7 days at the dose of 0.1 mg/kg/day in our institute between January 1991 and February 1992. Results. Of 23 patients, 19 (83%) achieved a CR and 4 (17%) a partial response (PR), with an overall response rate of 100%. After a median follow-up of 102 months (range: 96-108), there have been 9 (39%) relapses. In the PR subset 100% of patients relapsed within the first 45 months of follow-up. In the group of patients who obtained a CR, 26% relapsed; all these relapses occurred between 54 and 86 months. Overall the median time to relapse was 54 months (range: 16-86). All relapsed patients were retreated with 2-CdA at the dose of 0.15 mg/kg/day for 5 days in a 2-hour infusion, and 67% and 22% then obtained CR or PR, respectively. The russian duramen of this second response was 48 months (range: 22-80). All but one of these patients still maintain the second response to 2-CdA. The 9-year overall and the relapse-free survivals are 91% and 70%, respectively. Interpretation and Conclusions. In HCL patients a single dose of 2-CdA induces a long-term CR with a 9-year survival > 90%. Over 50% of patients appear to be clinically cured by this procedure, but the lack of a long-term plateau in the relapse-free survival curve means caution on this point is still warranted. (C) 2000, Ferrata Storti Foundation.

KW - 2-CdA

KW - 9-year follow-up

KW - HCL

KW - Re-treated patients

UR - http://www.scopus.com/inward/record.url?scp=0033786707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033786707&partnerID=8YFLogxK

M3 - Article

C2 - 10980629

AN - SCOPUS:0033786707

VL - 85

SP - 922

EP - 925

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 9

ER -